growing questions about the company's future and what else might be in its pipeline joining me, jeff meachamo you want to hear from moderna and these results? >> hi, kelly great to be here i would say tomorrow when you look at the numbers, already guided fourth quarter. not a lot of surprise. also given guidance for spike backs for 2022 but you're right the story is really, what's the encore to covid-19 definitely moving from phase two to phase three and then potentially approval in the next couple year, but that's pretty much it, though. i think focus will be, what do you do with the cash focus also be what about the other non-infectious disease eligible of the vaccine portfolio. >> sure. say they did have success with flu rsc or a combo of all three. where do you think the stock would go >> definitely there's a lot of up sides to it but i would say, though, there's a lot of value that's already assumed for spike backs in the form of a combination either with flu or rsv or both. next three to five years consensus assuming 7 billion in sales, about 4 and change. some of that i think is price